142 related articles for article (PubMed ID: 28944423)
1. Differential DNA Hydroxymethylation in Human Uterine Leiomyoma Cells Depending on the Phase of Menstrual Cycle and Presence of MED12 Gene Mutations.
Kol'tsova AS; Pendina AA; Efimova OA; Kaminskaya AN; Tikhonov AV; Osinovskaya NS; Sultanov IY; Shved NY; Kakhiani MI; Baranov VS
Bull Exp Biol Med; 2017 Sep; 163(5):646-649. PubMed ID: 28944423
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours.
Matsubara A; Sekine S; Yoshida M; Yoshida A; Taniguchi H; Kushima R; Tsuda H; Kanai Y
Histopathology; 2013 Mar; 62(4):657-61. PubMed ID: 23347103
[TBL] [Abstract][Full Text] [Related]
3. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
Croce S; Chibon F
Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152
[TBL] [Abstract][Full Text] [Related]
4. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities.
Asano R; Asai-Sato M; Matsukuma S; Mizushima T; Taguri M; Yoshihara M; Inada M; Fukui A; Suzuki Y; Miyagi Y; Miyagi E
Fertil Steril; 2019 Jan; 111(1):178-185. PubMed ID: 30554729
[TBL] [Abstract][Full Text] [Related]
5. The study of MED12 gene mutations in uterine leiomyomas from Iranian patients.
Sadeghi S; Khorrami M; Amin-Beidokhti M; Abbasi M; Kamalian Z; Irani S; Omrani M; Azmoodeh O; Mirfakhraie R
Tumour Biol; 2016 Feb; 37(2):1567-71. PubMed ID: 26298726
[TBL] [Abstract][Full Text] [Related]
6. Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyoma.
Di Tommaso S; Tinelli A; Malvasi A; Massari S
Mol Hum Reprod; 2014 Oct; 20(10):1009-15. PubMed ID: 25015674
[TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors.
Je EM; Kim MR; Min KO; Yoo NJ; Lee SH
Int J Cancer; 2012 Sep; 131(6):E1044-7. PubMed ID: 22532225
[TBL] [Abstract][Full Text] [Related]
8. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
9. MED12 mutation frequency in unselected sporadic uterine leiomyomas.
Heinonen HR; Sarvilinna NS; Sjöberg J; Kämpjärvi K; Pitkänen E; Vahteristo P; Mäkinen N; Aaltonen LA
Fertil Steril; 2014 Oct; 102(4):1137-42. PubMed ID: 25108465
[TBL] [Abstract][Full Text] [Related]
10. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
[TBL] [Abstract][Full Text] [Related]
11. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.
Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H
Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796
[TBL] [Abstract][Full Text] [Related]
13. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
Schwetye KE; Pfeifer JD; Duncavage EJ
Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
[TBL] [Abstract][Full Text] [Related]
14. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
15. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
Mäkinen N; Mehine M; Tolvanen J; Kaasinen E; Li Y; Lehtonen HJ; Gentile M; Yan J; Enge M; Taipale M; Aavikko M; Katainen R; Virolainen E; Böhling T; Koski TA; Launonen V; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
Science; 2011 Oct; 334(6053):252-5. PubMed ID: 21868628
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.
Commandeur AE; Styer AK; Teixeira JM
Hum Reprod Update; 2015; 21(5):593-615. PubMed ID: 26141720
[TBL] [Abstract][Full Text] [Related]
17. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
18. Analysis of
Lee M; Cheon K; Chae B; Hwang H; Kim HK; Chung YJ; Song JY; Cho HH; Kim JH; Kim MR
Int J Med Sci; 2018; 15(2):124-128. PubMed ID: 29333096
[TBL] [Abstract][Full Text] [Related]
19. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.
Turunen M; Spaeth JM; Keskitalo S; Park MJ; Kivioja T; Clark AD; Mäkinen N; Gao F; Palin K; Nurkkala H; Vähärautio A; Aavikko M; Kämpjärvi K; Vahteristo P; Kim CA; Aaltonen LA; Varjosalo M; Taipale J; Boyer TG
Cell Rep; 2014 May; 7(3):654-60. PubMed ID: 24746821
[TBL] [Abstract][Full Text] [Related]
20. MED12 alterations in both human benign and malignant uterine soft tissue tumors.
Pérot G; Croce S; Ribeiro A; Lagarde P; Velasco V; Neuville A; Coindre JM; Stoeckle E; Floquet A; MacGrogan G; Chibon F
PLoS One; 2012; 7(6):e40015. PubMed ID: 22768200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]